187 related articles for article (PubMed ID: 37756582)
41. Aspirin and NSAIDs for the prevention of colorectal cancer.
Baron JA
Recent Results Cancer Res; 2009; 181():223-9. PubMed ID: 19213572
[TBL] [Abstract][Full Text] [Related]
42. CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment.
Barry EL; Poole EM; Baron JA; Makar KW; Mott LA; Sandler RS; Ahnen DJ; Bresalier RS; McKeown-Eyssen GE; Ulrich CM
Cancer Causes Control; 2013 Jan; 24(1):47-54. PubMed ID: 23081681
[TBL] [Abstract][Full Text] [Related]
43. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.
Burn J; Gerdes AM; Macrae F; Mecklin JP; Moeslein G; Olschwang S; Eccles D; Evans DG; Maher ER; Bertario L; Bisgaard ML; Dunlop MG; Ho JW; Hodgson SV; Lindblom A; Lubinski J; Morrison PJ; Murday V; Ramesar R; Side L; Scott RJ; Thomas HJ; Vasen HF; Barker G; Crawford G; Elliott F; Movahedi M; Pylvanainen K; Wijnen JT; Fodde R; Lynch HT; Mathers JC; Bishop DT;
Lancet; 2011 Dec; 378(9809):2081-7. PubMed ID: 22036019
[TBL] [Abstract][Full Text] [Related]
44. Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
Gill S; Sinicrope FA
Semin Oncol; 2005 Feb; 32(1):24-34. PubMed ID: 15726503
[TBL] [Abstract][Full Text] [Related]
45. Nonsteroidal anti-inflammatory drug use and risk of adenomatous and hyperplastic polyps.
Murff HJ; Shrubsole MJ; Chen Z; Smalley WE; Chen H; Shyr Y; Ness RM; Zheng W
Cancer Prev Res (Phila); 2011 Nov; 4(11):1799-807. PubMed ID: 21764857
[TBL] [Abstract][Full Text] [Related]
46. C-reactive protein genotypes and haplotypes, polymorphisms in NSAID-metabolizing enzymes, and risk of colorectal polyps.
Poole EM; Bigler J; Whitton J; Sibert JG; Potter JD; Ulrich CM
Pharmacogenet Genomics; 2009 Feb; 19(2):113-20. PubMed ID: 19077918
[TBL] [Abstract][Full Text] [Related]
47. Aspirin as a chemoprevention agent for colorectal cancer.
Lee CS; McNamara D; O'Morain CA
Curr Drug Metab; 2012 Nov; 13(9):1313-22. PubMed ID: 22493984
[TBL] [Abstract][Full Text] [Related]
48. Chemoprevention of colorectal neoplasia.
Wakeman C; Keenan J; Eteuati J; Hollington P; Eglinton T; Frizelle F
ANZ J Surg; 2017 Dec; 87(12):E228-E232. PubMed ID: 26686322
[TBL] [Abstract][Full Text] [Related]
49. Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States).
Tangrea JA; Albert PS; Lanza E; Woodson K; Corle D; Hasson M; Burt R; Caan B; Paskett E; Iber F; Kikendall JW; Lance P; Shike M; Weissfeld J; Schatzkin A;
Cancer Causes Control; 2003 Jun; 14(5):403-11. PubMed ID: 12946034
[TBL] [Abstract][Full Text] [Related]
50. Vitamins B2, B6, and B12 and risk of new colorectal adenomas in a randomized trial of aspirin use and folic acid supplementation.
Figueiredo JC; Levine AJ; Grau MV; Midttun O; Ueland PM; Ahnen DJ; Barry EL; Tsang S; Munroe D; Ali I; Haile RW; Sandler RS; Baron JA
Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2136-45. PubMed ID: 18708408
[TBL] [Abstract][Full Text] [Related]
51. Celecoxib as adjunctive therapy for treatment of colorectal cancer.
North GL
Ann Pharmacother; 2001 Dec; 35(12):1638-43. PubMed ID: 11793634
[TBL] [Abstract][Full Text] [Related]
52. Risk of lower gastrointestinal bleeding and colorectal neoplasms following initiation of low-dose aspirin: a Danish population-based cohort study.
Troelsen FS; Farkas DK; Erichsen R; Sørensen HT
BMJ Open Gastroenterol; 2020 Jul; 7(1):. PubMed ID: 32719046
[TBL] [Abstract][Full Text] [Related]
53. Cyclooxygenase as a target for colorectal cancer chemoprevention.
Moreira L; Castells A
Curr Drug Targets; 2011 Dec; 12(13):1888-94. PubMed ID: 21158711
[TBL] [Abstract][Full Text] [Related]
54. Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention.
Barry EL; Baron JA; Bhat S; Grau MV; Burke CA; Sandler RS; Ahnen DJ; Haile RW; O'Brien TG
J Natl Cancer Inst; 2006 Oct; 98(20):1494-500. PubMed ID: 17047198
[TBL] [Abstract][Full Text] [Related]
55. Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway.
Slattery ML; Samowitz W; Hoffman M; Ma KN; Levin TR; Neuhausen S
Cancer Epidemiol Biomarkers Prev; 2004 Apr; 13(4):538-45. PubMed ID: 15066917
[TBL] [Abstract][Full Text] [Related]
56. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.
Chan AT; Ogino S; Fuchs CS
N Engl J Med; 2007 May; 356(21):2131-42. PubMed ID: 17522398
[TBL] [Abstract][Full Text] [Related]
57. Aspirin and gastrointestinal cancer.
Thun MJ
Adv Exp Med Biol; 1997; 400A():395-402. PubMed ID: 9547582
[TBL] [Abstract][Full Text] [Related]
58. Low dose aspirin, COX-inhibition and chemoprevention of colorectal cancer.
Benamouzig R; Uzzan B; Little J; Chaussade S
Curr Top Med Chem; 2005; 5(5):493-503. PubMed ID: 15974944
[TBL] [Abstract][Full Text] [Related]
59. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.
Dubé C; Rostom A; Lewin G; Tsertsvadze A; Barrowman N; Code C; Sampson M; Moher D;
Ann Intern Med; 2007 Mar; 146(5):365-75. PubMed ID: 17339622
[TBL] [Abstract][Full Text] [Related]
60. Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study.
Grau MV; Sandler RS; McKeown-Eyssen G; Bresalier RS; Haile RW; Barry EL; Ahnen DJ; Gui J; Summers RW; Baron JA
J Natl Cancer Inst; 2009 Feb; 101(4):267-76. PubMed ID: 19211442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
